Molecular diagnostics of myeloproliferative neoplasms

MPN & MPNr-EuroNet, Stephen E. Langabeer*, Hajnalka Andrikovics, Julia Asp, Beatriz Bellosillo, Serge Carillo, Karl Haslam, Lasse Kjaer, Eric Lippert, Olivier Mansier, Elisabeth Oppliger Leibundgut, Melanie J. Percy, Naomi Porret, Lars Palmqvist, Jiri Schwarz, Mary F. Mcmullin, Susanne Schnittger, Niels Pallisgaard, Sylvie Hermouet

*Corresponding author

Publikation: Bidrag til tidsskriftReviewpeer review


Since the discovery of the JAK2 V617F mutation in the majority of the myeloproliferative neoplasms (MPN) of polycythemia vera, essential thrombocythemia and primary myelofibrosis ten years ago, further MPN-specific mutational events, notably in JAK2 exon 12, MPL exon 10 and CALR exon 9 have been identified. These discoveries have been rapidly incorporated into evolving molecular diagnostic algorithms. Whilst many of these mutations appear to have prognostic implications, establishing MPN diagnosis is of immediate clinical importance with selection, implementation and the continual evaluation of the appropriate laboratory methodology to achieve this diagnosis similarly vital. The advantages and limitations of these approaches in identifying and quantitating the common MPN-associated mutations are considered herein with particular regard to their clinical utility. The evolution of molecular diagnostic applications and platforms has occurred in parallel with the discovery of MPN-associated mutations, and it therefore appears likely that emerging technologies such as next-generation sequencing and digital PCR will in the future play an increasing role in the molecular diagnosis of MPN.

TidsskriftEuropean Journal of Haematology
Udgave nummer4
Sider (fra-til)270-279
Antal sider10
StatusUdgivet - 1 okt. 2015
Udgivet eksterntJa

Bibliografisk note


Citer dette